Get the Daily Brief
Latest Biotech News
CRISPR-Enhanced CAR-T Cells Show Improved Solid Tumor Activity
Massachusetts General Hospital researchers engineered IFN-γ-resistant CD28 CAR-T cells that partially evade activation-induced cell death, enhancing survival and anti-tumor efficacy in multiple...
Nanopore-Only Genome Assemblies Enabled by Novel Algorithm
Dana-Farber researchers developed Hifiasm (ONT), an algorithm capable of assembling near telomere-to-telomere human genomes using standard nanopore sequencing reads without requiring ultra-long...
Data-Driven Subtypes Reveal Parkinson’s Disease Heterogeneity
A study leveraging deep gray matter atrophy and dopamine availability imaging identified distinct clinical subtypes of early Parkinson’s disease. The subtypes correlate with specific phenotypic...
KalVista Drug Approval Delay Cited Due to FDA Resource Constraints
KalVista Pharmaceuticals disclosed FDA postponement of its regulatory decision for an oral on-demand hereditary angioedema treatment, attributing the delay to the agency’s heavy workload and...
Wojcicki’s Nonprofit Triumphs: TTAM Secures 23andMe for $305 Million
Anne Wojcicki's TTAM Research Institute outbid Regeneron Pharmaceuticals to acquire 23andMe's assets for $305 million in a second auction, securing the company's Personal Genome Service and more....
Seed Funding Boosts Elkedonia’s Neuroplastogen for Depression
Elkedonia SAS raised €11 million in a seed round to support clinical development of its first-in-class ELK-1 inhibitor for refractory depression, targeting neuroplasticity pathways. This funding...
ADC Therapeutics Cuts UK R&D and Workforce by 30%
Following the discontinuation of key clinical candidates, ADC Therapeutics is closing its UK research site and reducing its workforce by 30%. The restructuring aims to refocus resources on...
Wojcicki’s Nonprofit Triumphs: TTAM Secures 23andMe for $305 Million
Anne Wojcicki's TTAM Research Institute outbids Regeneron to acquire 23andMe assets for $305 million, reinforcing the company's founding vision. The nonprofit commits to strict privacy measures,...
FDA Greenlights Pembrolizumab for Resectable Head and Neck Cancer
The FDA has approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, marking a significant therapeutic advancement. This...
UC Scientists Reveal Protein Structures Driving Inflammatory Diseases
University of Cincinnati researchers used cryogenic electron microscopy to visualize for the first time the ADAM17 enzyme bound to its regulator iRhom2, key to inflammatory signaling linked to...
Proteomics Integration Advances Multiomics Research Platforms
Ultima Genomics and collaborators enhance multiomics capabilities by integrating gene sequencing and proteomics technologies to better characterize biological systems. Partnerships with firms like...
New Cooling Technology Aims to Cut Data Center Energy Use
University of California San Diego engineers developed a novel fiber membrane technology that passively cools data centers through evaporation, potentially halving energy consumption versus...
Seed Round Fuels Elkedonia’s Neuroplastogen for Depression Treatment
French startup Elkedonia secured €11 million in seed funding to advance its ELK-1 inhibitor targeting refractory depression. ELK-1 influences neuroplasticity and reward circuits implicated in mood...
Cancer Immunotherapy Advances: Dual-Target CAR-T Shows Promise in Lymphoma
Johnson & Johnson presents clinical data from a Phase 1b trial of a dual CD19/CD20-targeted CAR-T therapy for relapsed or refractory large B-cell lymphoma. High objective and complete response...
Shift in Biotechnology Governance Marking 50 Years of Asilomar Principles
Following the 50th anniversary of the 1975 Asilomar Conference on Recombinant DNA, Rice University archived 27 entreaties emphasizing governance of modern biotechnology. These documents address...
Novo Nordisk Advances Amycretin Obesity Drug into Phase 3 Trials
Novo Nordisk plans Phase 3 clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist, investigating both injectable and oral formulations. The move comes after positive phase 1b/2a...
Parkinson’s Disease Penetrance Linked to GBA1 Variant Severity and Genetics
A study in npj Parkinson’s Disease identifies variant severity and polygenic background as determinants of Parkinson’s disease penetrance among GBA1 mutation carriers. The findings enhance...
Fusobacterium nucleatum: Unveiling Cancer’s Microbial Ally in Colorectal Disease
A comprehensive review by researchers at the Institute of Process Engineering illuminates the extensive role of Fusobacterium nucleatum in colorectal cancer development. The bacterium's ability to...
BioNTech Buys CureVac to Accelerate Cancer Therapy Development
BioNTech's $1.25 billion all-stock acquisition of CureVac strengthens its mRNA manufacturing and cancer immunotherapy pipeline. By integrating CureVac’s manufacturing capabilities and resolving...
TIGIT Setbacks Expose Pitfalls of Immunotherapy Hype
Failures of major anti-TIGIT antibody candidates, following promising early results, reveal challenges in immuno-oncology development. Key phase 3 trials halted due to lack of efficacy underscore...